From Customer to CEO: Kaitlyn Talamante Acquires LadyBoss, the Women’s Health Brand Empowering Hundreds of Thousands Since 2014

From Customer to CEO: Kaitlyn Talamante Acquires LadyBoss, the Women’s Health Brand Empowering Hundreds of Thousands Since 2014

LadyBoss, the women’s health and lifestyle brand founded in 2014 by Kaelin and Brandon Poulin, later sold to Russell Brunson in 2022, announces its new owner, Kaitlyn Talamante. A former LadyBoss customer turned CEO, Talamante’s journey from personal transformation to leading the brand represents a full-circle story of empowerment, growth, and vision for the future. - September 05, 2025 - LadyBoss

CABRI Fellowship Program Opens for Undergraduate Research Applicants

The Cayman Biomedical Research Institute (CABRI) has announced that applications are now open for their undergraduate research fellowships. Applications may be submitted on the CABRI website from August 11, 2025 through September 29, 2025. - August 15, 2025 - Cayman Chemical Company

New Book “Life Lessons From the Overhead Bin: A Flight Attendant’s Advice on How to Be Fit, Fearless and Fulfilled After 50” Uplifts and Inspires Women to Soar in Midlife

New Book “Life Lessons From the Overhead Bin: A Flight Attendant’s Advice on How to Be Fit, Fearless and Fulfilled After 50” Uplifts and Inspires Women to Soar in Midlife

In her debut book, author Helen Fritsch weaves observations and stories from her 40-year career in the sky with her unique inspirational advice and practical tips. - August 14, 2025 - Helen Fritsch

YOLO Immune Inc. Emerges from Stealth Mode

YOLO Immune Inc. has emerged from stealth mode to unveil its human-centric drug discovery process and to announce the promotion of its founding research team. YOLO Immune is a venture-backed biotech company developing precision immunotherapies for the treatment of serious human diseases. The... - July 31, 2025 - YOLO Immune Inc

ERBESSD INSTRUMENTS Continues Global Expansion

ERBESSD INSTRUMENTS Continues Global Expansion

ERBESSD INSTRUMENTS a global leader in dynamic balancing, vibration analysis, machinery health, and process health instrumentation and optimization announces expansion to Latin America. - July 25, 2025 - ERBESSD INSTRUMENTS

GENINVO Celebrates 8 Years of Innovation and Growth in the Life Sciences Industry

GENINVO, a leading provider of transformative digital solutions for the life sciences sector, proudly celebrates its 8th anniversary—a journey marked by innovation, collaboration, and impactful contributions across global healthcare and pharmaceutical domains. From a vision sparked eight... - July 22, 2025 - GenInvo, Inc.

Aphora Health Acquires CareNexis to Accelerate Innovation in Specialty Pharmacy Benefits and AI-Driven Insights for Self-Insured Employers

Aphora Health, a leading provider of cost containment solutions and advanced pharmacy benefit strategies for self-insured employers, announces the acquisition of CareNexis, a digital health company known for its proprietary consumer health intelligence and engagement platform. This acquisition... - July 10, 2025 - Aphora Health

Alera Bio Launches to Advance Breakthrough Therapies for Rare Neurological Disorders

Alera Bio Launches to Advance Breakthrough Therapies for Rare Neurological Disorders

Chicago-based Alera Bio has launched with a mission to develop treatments for ultra-rare and neglected neurological disorders, especially in children. Combining scientific innovation with patient urgency, the company will pursue both novel and repurposed therapies via orphan drug and 505(b)(2) pathways. With a lean, capital-efficient model, Alera Bio aims to rapidly advance therapies that address critical gaps in care. - July 03, 2025 - Alera Bio

Fantastic Nutrition Launches Creatine Fantastic, a Science-Based Supplement Featuring Creatine and myHMB® for Enhanced Muscle Strength and Recovery

Fantastic Nutrition Launches Creatine Fantastic, a Science-Based Supplement Featuring Creatine and myHMB® for Enhanced Muscle Strength and Recovery

Research shows that combining creatine with myHMB can increase lean muscle mass up to 30% more than creatine alone (Wilson et al., 2014, Journal of the International Society of Sports Nutrition). This blend not only helps build muscle and recover faster, but also reduces muscle degradation, enhances athletic performance, and supports cognitive function—a total performance formula for both body and mind. - June 15, 2025 - Fantastic Nutrition

H3Tech Welcomes Ruiban Coutinho as AI Healthtech Consultant

H3Tech Welcomes Ruiban Coutinho as AI Healthtech Consultant

H3Tech, a healthcare technology and consulting firm, has appointed Ruiban Coutinho as AI Healthtech Consultant. With 14 years of experience in data analytics and business intelligence, Coutinho will leverage his expertise in AI, SAP BW/HANA, and Power BI to enhance H3Tech’s AI-driven healthcare solutions. - June 06, 2025 - H3Tech

Good Mana Knows the Secret to Powerful Health Benefits: ʻŌlena Gold Turmeric - A Premium Organic Supplement Grown in Nutrient-Dense Hawaiian Soil

Good Mana Knows the Secret to Powerful Health Benefits: ʻŌlena Gold Turmeric - A Premium Organic Supplement Grown in Nutrient-Dense Hawaiian Soil

Good Mana, based in Waimanalo, Hawai'i, is raising the industry standard for potency, purity and traceability of turmeric supplements with its premium ʻŌlena Gold Turmeric brand. - May 24, 2025 - Good Mana

New QualiFam Autism Protocol Now Available in U.S. Treats Root Biological Causes Behind Symptoms

Developed by physician-scientist Dr. Ken Alibek, the QualiFam Protocol delivers results in as little as three months by targeting immune and infection-linked triggers. - May 16, 2025 - QualiFam

Microvascular Therapeutics: Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)

Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon,... - May 15, 2025 - Microvascular Therapeutics, Inc.

Truvy® and Sweet Minerals Partner to Expand Global Health & Beauty Opportunities via Bytru.com

Truvy® has integrated the product and multi-level marketing (MLM) operations of Sweet Minerals into its business at Bytru, making Sweet Minerals’ celebrated beauty products available to a broader global audience. - May 12, 2025 - Truvy

Vetirus Pharmaceuticals Acquires Enso Discoveries to Expand Regenerative Medicine Portfolio

Vetirus Pharmaceuticals, a multinational company headquartered in Naples, Florida, and London, UK, announced its acquisition of Enso Discoveries, LLC, a Manhattan, Kansas-based biotech company specializing in regenerative medicine. The acquisition was revealed at the 10th annual Animal Health, Nutrition, and Technology Innovation Europe. - April 30, 2025 - Vetirus Animal Health

Mirror Biologics Announces Publication of Clinical Results Showing Potential for Allo-Priming to Provide Broad Protection to Elderly from Respiratory Viral Infection

Mirror Biologics Announces Publication of Clinical Results Showing Potential for Allo-Priming to Provide Broad Protection to Elderly from Respiratory Viral Infection

A new approach for pandemic preparedness and protection of the elderly from any type of respiratory viral infection. Five injections over two weeks provides possible universal viral protection without need for booster shots. - April 28, 2025 - Mirror Biologics, Inc.

International Vitamin Corporation (IVC) Appoints Nora Dowell as Senior Vice President of Quality, Regulatory, and R&D

International Vitamin Corporation (IVC) Appoints Nora Dowell as Senior Vice President of Quality, Regulatory, and R&D

IVC is pleased to announce the appointment of Nora Dowell as Senior Vice President of Quality, Regulatory, and R&D, marking a significant step forward in the company’s ongoing commitment to delivering high-quality, compliant, and innovative health and wellness products. Nora brings more than 30 years of experience in regulatory compliance and quality management systems, with deep expertise in cGMP, QMS, FSMA/FSVP, training, auditing, labeling, and supplier qualifications. - April 26, 2025 - International Vitamin Corporation

Parvus Announces Achievement of First Milestone from its Collaboration Agreement with AbbVie to Develop IBD Therapies Based on the Parvus Nanomedicine Platform Technology

IND-enabling nonclinical and manufacturing activities executed by Parvus met prospective criteria resulting in the first milestone payment from AbbVie. - April 21, 2025 - Parvus Therapeutics U.S., Inc.

GENINVO Announces Its Latest Innovation – Confidential Information Scanner (CIS) Tool

GENINVO, a leading provider of life science technology solutions, is proud to announce the launch of its latest innovation – the Confidential Information Scanner (CIS) Tool. This tool is designed to help organizations identify publicly available company confidential information (CCI) across... - April 12, 2025 - GenInvo, Inc.

Minus K Congratulates to the following winners of their 2024/2025 Educational Giveaway

Celebrating its’ tenth year of their U.S. Educational Giveaway, Minus K Technology has to-date granted over $100,000 of its superior performing patented Negative-Stiffness low-frequency passive mechanical vibration isolators to colleges and universities in the USA. - April 03, 2025 - Minus K Technology Inc.

Apeximmune Therapeutics Announces Successful Close of Series A Fundraising Round to Advance Next-Generation Immunotherapies

Apeximmune Therapeutics Announces Successful Close of Series A Fundraising Round to Advance Next-Generation Immunotherapies

Apeximmune Therapeutics, a biotechnology company pioneering next-generation immunotherapies, today announced the successful close of its Series A financing round, raising $21.3 million, exceeding its original goal of $20 million. The funding was led by PharmaEssentia Corporation, with participation... - April 01, 2025 - Apeximmune Therapeutics

Huntington Study Group Announces Executive Director of Clinical Operations

Huntington Study Group Announces Executive Director of Clinical Operations

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to introduce Carolyn Schultz-Walter as the Executive Director of Clinical Operations. With over 25 years of global clinical operations experience spanning both sponsor and clinical research... - March 31, 2025 - Huntington Study Group

Thar Process and Clean Heat Technologies Integrate CO2 Heat Pump Technology to Make Supercritical CO2 Technology a Low Cost Solution

Thar Process and Clean Heat Technologies Integrate CO2 Heat Pump Technology to Make Supercritical CO2 Technology a Low Cost Solution

Thar Process and Clean Heat Technologies have successfully engineered, integrated and installed electric heat pumps using CO2 - R744 - as the upcycled, natural refrigerant. The technology partnership means that Thar Process' clients can benefit from lower operating costs. Thar is known for it's innovative use of CO2 for extracting flavors, fragrances, medicinal and therapeutic compounds both in it's GMP certified facility in Pittsburgh and at client sites globally. - March 24, 2025 - Thar Process

SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025

SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy. - March 21, 2025 - SignaBlok, Inc.

SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025

SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in the lungs and reverses fibrosis. - March 21, 2025 - SignaBlok, Inc.

West Bengal Chemical Industries Limited Introduces Liposomal Skincare Technology

Liposomal technology, an advance technology, involves encapsulating active ingredients within lipid bilayers. - March 11, 2025 - West Bengal Chemical Industries Limited

HistAI Unveils Groundbreaking SPIDER Initiative at HIMSS Conference

At the HIMSS Conference, HistAI announced the SPIDER Initiative, an open-source project set to become the largest supervised medical imaging dataset. The initiative will compile more than 50 millions of fully annotated images from 20 organs and 400 morphologies, advancing AI-driven diagnostics, precision medicine, and drug development. The first release includes more than 4 millions of images from 6K Whole Slide Images (WSIs) across Skin, Colorectal, and Thorax. Available starting today. - March 06, 2025 - HistAI

matrihealth GmbH Qualifies Soluble Elastin Hydrolysate matripure® for Use in Cosmetics

matrihealth GmbH has qualified matripure® elastin for use in cosmetics, providing manufacturers with a high-quality raw material made in Germany. - March 06, 2025 - matrihealth GmbH

Regenexx® Corporate Program's Dr. Mark Testa Wins the YOU Powered Symposium 2025 Most Influential Clinician in Insurance Award

Regenexx® Corporate Program's Dr. Mark Testa Wins the YOU Powered Symposium 2025 Most Influential Clinician in Insurance Award

The YOU Powered Symposium is the leading annual event for "bold benefits trailblazers." It brings together hundreds of benefit professionals, solution providers, clinicians, and employers to combine diverse expertise in an effort to reform the US healthcare system on behalf of every patient. - March 04, 2025 - Regenexx Corporate Program

Trump-Era Administration Drug Development & Outsourcing Impact Report

How Tariffs and RFK Jr.’s HHS Appointment May Shift Drug Development & Outsourcing - February 27, 2025 - Life Science Strategy Group, LLC

Two Peoria Residents Win $20,000 in National Transformation Contest

Two Peoria Residents Win $20,000 in National Transformation Contest

Wayne Galpin and Kaitlyn Willis of FXB Peoria have won the 2024 Farrell’s National Challenge, each earning $10,000 for their remarkable yearlong fitness transformations. Farrell’s eXtreme Bodyshaping (FXB) combines kickboxing, strength training, nutrition coaching, and accountability to help members achieve lasting health results. Their dedication not only transformed their lives but also inspired their community. - February 19, 2025 - Farrell's Extreme Body Shaping

Legacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Member of the Roche Group

Legacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Member of the Roche Group

Legacy Pharma Inc. SEZC (“Legacy Pharma” or the “Company”), a specialty pharmaceutical company, announced the completion of the acquisition of InterMune, Inc. (“InterMune”) and the intellectual property rights to Esbriet® (pirfenidone) in the United States... - February 06, 2025 - Legacy Pharma Inc. SEZC

Purple Diamond Hosting Exclusive Webinar on Pharmaceutical Packaging Validation and Product Integrity

Purple Diamond, a leading ISO-accredited package testing lab, will host a free webinar on February 4, at 2 pm EST. "Protecting Pharma Integrity: The Science of Packaging Validation" will provide insights into testing methodologies and tools critical for ensuring pharmaceutical packaging safety and compliance. - January 16, 2025 - Purple Diamond Testing

Regenexx Announces Dr. Philippe Hernigou as New Medical Director of Clinical Research

Regenexx®, a leader in regenerative medicine and advanced orthobiologics, is proud to announce that Dr. Philippe Hernigou, a globally recognized expert in autologous cell therapy and musculoskeletal regeneration, has joined the company as its new Medical Director of Clinical Research. Dr. - December 11, 2024 - Regenexx Corporate Program

SeroRepair Announces New Office Location to Support Expansion and Growth

SeroRepair Announces New Office Location to Support Expansion and Growth

SeroRepair, an eye serum leader in the veterinary industry announces expansion to a new office location for increased operations, customer service, and product development, positioning the company for continued success in the veterinary industry. With an ever-growing demand for high-quality eye care products for small and large animals and a need for increasing efficiency in veterinary practices, SeroRepair has experienced significant growth over the past year. - December 10, 2024 - SeroRepair

Arizona Pharmacy Association Appoints Garet Turner as New CEO

Arizona Pharmacy Association Appoints Garet Turner as New CEO

Today, the Arizona Pharmacy Association (AzPA), the leading voice for Arizona’s pharmacy professionals, announced the appointment of Garet Turner as its new Chief Executive Officer. Turner, a seasoned management, membership and fundraising professional will take the helm on January... - December 07, 2024 - Arizona Pharmacy Association

HealthPub Publishes Comprehensive FODMAP Statistics Report

HealthPub Publishes Comprehensive FODMAP Statistics Report

Research highlights that up to 86% of IBS sufferers experience significant symptom relief by following a low-FODMAP diet, emphasizing its effectiveness in managing bloating, abdominal pain, and irregular bowel movements. - November 23, 2024 - Healthpub

Polar Lab Projects Redefines Laboratory Relocation Standards with Global, Single-Source Logistics Solution

Polar Lab Projects Redefines Laboratory Relocation Standards with Global, Single-Source Logistics Solution

Polar Lab Projects is setting a new standard in laboratory relocations and logistics, offering a single-source, seamless solution tailored to the life sciences industry worldwide. With an extensive network of industry experts, they provide unmatched service excellence, meeting clients' needs wherever they operate. - November 06, 2024 - Polar Lab Projects LLC

VitaMist® New Wholesale Purchasing Service

New Wholesale Business Offering is Geared for Distributors and Retailers - November 02, 2024 - VitaMist

VITAMIST® Launches New MultiPlus Multivitamin Oral Spray

Multi-Vitamin Plus Oral Spray is a Comprehensive Blend of Essential Nutrients - November 02, 2024 - VitaMist

Novugen Pharma Malaysia Achieves Zero Form 483 Citations in Recent USFDA Audit

Novugen Pharma Malaysia Achieves Zero Form 483 Citations in Recent USFDA Audit

Novugen Pharma Sdn. Bhd. proudly announces the successful completion of recent USFDA audit, achieving zero Form 483 citations and No Action Indicated (NAI) status—the highest level of compliance for USFDA-registered manufacturing facilities. This milestone positions Novugen among a select few global companies meeting these standards and reflects the dedication of its team. - October 29, 2024 - Novugen

Bloom Lab Launches The Menopause Playbook on World Menopause Day

In honour of World Menopause Day, Bloom Lab is launching The Menopause Playbook, a no-nonsense guide for today's forward-thinking woman with everything she needs to know to tackle menopause like a pro without having to sift through endless books, articles or studies. Created by Kristina von... - October 20, 2024 - Bloom Lab

Nebula Scientific Announces Private Label Service

New Private White Label Service for Oral Spray Vitamins and Supplements - October 19, 2024 - VitaMist

Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-cell (Treg) Inducing pMHC Nanomedicine Therapy

Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PVT201 single ascending doses in healthy subjects and primary biliary cholangitis patients. - October 17, 2024 - Parvus Therapeutics U.S., Inc.

Aker BioMarine Launches New Website Dedicated to Krill Oil Science and Education

Aker BioMarine Launches New Website Dedicated to Krill Oil Science and Education

KrillOil.com, a new consumer website for all things related to krill oil, is launching today. - October 06, 2024 - Aker BioMarine

CURE Pharmaceutical Appoints Raymond Watt to Board of Directors

CURE Pharmaceutical, renowned for its innovative sublingual delivery systems, is proud to announce the appointment of Raymond Watt to its Board of Directors. - October 01, 2024 - CURE Pharmaceutical, Inc.

BÜHLMANN Laboratories AG Announces Worldwide Collaboration with Beckman Coulter for BUHLMANN fCAL® turbo and fPELA® turbo Assays

BÜHLMANN Laboratories AG Announces Worldwide Collaboration with Beckman Coulter for BUHLMANN fCAL® turbo and fPELA® turbo Assays

BÜHLMANN Laboratories AG, a leading manufacturer of specialty, high-quality in-vitro diagnostic and research assays, is pleased to announce the collaboration with Beckman Coulter for a worldwide distribution of the BÜHLMANN fCAL® turbo assay & BÜHLMANN fPELA® turbo assay... - September 26, 2024 - BUHLMANN Diagnostics Corp

Canaritech Announces the Launch of Operations, Offering Comprehensive Clinical Trial Solutions Across Latin America

Canaritech, a Contract Research Organization (CRO), has officially launched operations across Latin America, with offices in Mexico, Peru, Chile, and Colombia. The company offers a range of clinical trial services, including regulatory consulting, trial management, decentralized clinical trials, and post-market studies. Canaritech aims to drive innovation in clinical research by improving trial efficiency and increasing patient access through localized expertise and advanced technologies. - September 22, 2024 - Canaritech

Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders

Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders

Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.

Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100

Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.

Press Releases 51 - 100 of 3,245